Patents by Inventor Venkateshwar Rao Gummadi

Venkateshwar Rao Gummadi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Indazole Compounds as IRAK4 Inhibitors
    Publication number: 20160326151
    Abstract: The present invention provides indazole compounds of formula (I), which are therapeutically useful as kinase inhibitors, particularly IRAK4 inhibitors, wherein Z1, Z2, R1, R2, R3, ‘m’ and ‘n’ have the meanings given in the specification, and pharmaceutically acceptable salts or stereoisomers thereof that are useful in the treatment and prevention of diseases or disorders, in particular their use in diseases or disorders mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical compositions comprising at least one of the compounds of the compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient.
    Type: Application
    Filed: January 7, 2015
    Publication date: November 10, 2016
    Inventors: Venkateshwar Rao Gummadi, Susanta Samaijdar, Ajay Gupta
  • 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives as kinase inhibitors
    Patent number: 9353107
    Abstract: The present application relates to novel 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives of formula (I), as protein kinase inhibitors. The invention particularly relates to compounds of formula (I), preparation of compounds and pharmaceutical compositions thereof. The invention further relates to pharmaceutically acceptable salts and compositions comprising the said novel 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives and their use in the treatment of various disorders.
    Type: Grant
    Filed: July 1, 2013
    Date of Patent: May 31, 2016
    Assignees: Aurigene Discovery Technologies Limited, Um Pharmauji Sdn. Bhd.
    Inventors: Venkateshwar Rao Gummadi, Subramanya Hosahalli, Srinivas Nanduri, Girish Aggunda Renukappa
  • 17a-hydroxylase/C17,20-lyase inhibitors
    Patent number: 9339501
    Abstract: The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds of the present invention have been found to be useful as 17?-hydroxylase/C17,20-lyase inhibitors.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: May 17, 2016
    Assignee: NOVARTIS AG
    Inventors: Mark Gary Bock, Christoph Gaul, Venkateshwar Rao Gummadi, Saumitra Sengupta
  • 3-(Pyrazolyl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors
    Publication number: 20150336949
    Abstract: The present application relates to novel 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives of formula (I), as protein kinase inhibitors. The invention particularly relates to compounds of formula (I), preparation of compounds and pharmaceutical compositions thereof. The invention further relates to pharmaceutically acceptable salts and compositions comprising the said novel 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives and their use in the treatment of various disorders.
    Type: Application
    Filed: July 1, 2013
    Publication date: November 26, 2015
    Applicants: Um Pharmauji Sdn. Bhd., Aurigene Discovery Industrial Area
    Inventors: Venkateshwar Rao Gummadi, Subramanya Hosahalli, Srinivas Nanduri, Girish Aggunda Renukappa
  • 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS
    Publication number: 20150209356
    Abstract: The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds of the present invention have been found to be useful as 17?-hydroxylase/C17,20-lyase inhibitors.
    Type: Application
    Filed: April 9, 2015
    Publication date: July 30, 2015
    Applicant: Novartis AG
    Inventors: Mark Gary Bock, Christoph Gaul, Venkateshwar Rao Gummadi, Saumitra Sengupta
  • 5-(1H-Pyrazol-4-yl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors
    Publication number: 20150183781
    Abstract: The present application relates to novel 5-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine derivatives of formula (I), as protein kinase inhibitors. The invention particularly relates to compounds of formula (I), preparation of compounds and pharmaceutical compositions thereof. The invention further relates to prodrugs, derivatives, polymorphs, pharmaceutically acceptable salts and compositions comprising the said novel 5-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine compounds and their derivatives and their use in the treatment of various disorders.
    Type: Application
    Filed: July 25, 2013
    Publication date: July 2, 2015
    Applicants: Um Pharmauji Sdn. Bhd., Aurigene Discovery Technologies Limited
    Inventors: Venkateshwar Rao Gummadi, Subramanya Hosahalli, Srinivas Nanduri, Girish Aggunda Renukappa
  • 17?-hydroxylase/C-lyase inhibitors
    Patent number: 9029399
    Abstract: The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds of the present invention have been found to be useful as 17?-hydroxylase/C17,20-lyase inhibitors.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: May 12, 2015
    Assignee: Novartis AG
    Inventors: Mark Gary Bock, Christoph Gaul, Venkateshwar Rao Gummadi, Saumitra Sengupta
  • 17?-hydroxylase/C-lyase inhibitors
    Patent number: 8946260
    Abstract: The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, A and n are as defined herein. A deuteriated derivative of the compound of Formula (I) is also provided.
    Type: Grant
    Filed: September 14, 2011
    Date of Patent: February 3, 2015
    Assignee: Novartis AG
    Inventors: Mark Gary Bock, Christoph Gaul, Venkateshwar Rao Gummadi, Henrik Moebitz, Saumitra Sengupta
  • INHIBITORS OF CYP 17
    Publication number: 20140228394
    Abstract: The present invention provides compounds of Formula (I) and (II), or a pharmaceutically acceptable salts thereof, where R53, R54, p, q, and n are as defined herein. The compounds of the present invention have been found to be useful as 17?-hydroxylase/C17,20-lyase inhibitors.
    Type: Application
    Filed: April 21, 2014
    Publication date: August 14, 2014
    Applicant: Novartis AG
    Inventors: Mark Gary BOCK, Christoph GAUL, Venkateshwar Rao GUMMADI, Saumitra SENGUPTA
  • 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS
    Publication number: 20140228386
    Abstract: The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds of the present invention have been found to be useful as 17?-hydroxylase/C17,20-lyase inhibitors.
    Type: Application
    Filed: April 27, 2012
    Publication date: August 14, 2014
    Applicant: NOVARTIS AG
    Inventors: Mark Gary Bock, Christoph Gaul, Venkateshwar Rao Gummadi, Saumitra Sengupta
  • 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS
    Publication number: 20140045872
    Abstract: The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, A and n are as defined herein. A deuteriated derivative of the compound of Formula (I) is also provided.
    Type: Application
    Filed: September 14, 2011
    Publication date: February 13, 2014
    Applicant: NOVARTIS AG
    Inventors: Mark Gary Bock, Christoph Gaul, Venkateshwar Rao Gummadi, Henrik Moebitz, Saumitra Sengupta
  • Inhibitors of CYP 17
    Patent number: 8263635
    Abstract: The present invention provides compounds of Formula (I) and (II), or a pharmaceutically acceptable salts thereof, where R53, R54, p, q, and n are as defined herein. The compounds of the present invention have been found to be useful as 17?-hydroxylase/C17,20-lyase inhibitors.
    Type: Grant
    Filed: June 28, 2010
    Date of Patent: September 11, 2012
    Assignee: Novartis AG
    Inventors: Mark G. Bock, Christoph Gaul, Venkateshwar Rao Gummadi, Saumitra Sengupta
  • Inhibitors of CYP 17
    Publication number: 20100331326
    Abstract: The present invention provides compounds of Formula (I) and (II), or a pharmaceutically acceptable salts thereof, where R53, R54, p, q, and n are as defined herein. The compounds of the present invention have been found to be useful as 17?-hydroxylase/C17,20-lyase inhibitors.
    Type: Application
    Filed: June 28, 2010
    Publication date: December 30, 2010
    Inventors: Mark G. BOCK, Christoph GAUL, Venkateshwar Rao GUMMADI, Saumitra SENGUPTA